April 07, 2017
RealTime Dynamix™: Ulcerative Colitis US Q2
Ulcerative Colitis (UC) is a common form of inflammatory bowel diseases, currently affecting the lives of approximately 700,000 Americans. The introduction of biologics has changed the face of treatment for moderateto-severe UC patients. However, recent launches, an active pipeline, and the imminent introduction of biosimilars present an opportunity for major future shifts in the UC landscape.
RealTime Dynamix™: Ulcerative Colitis provides a close-quarters analysis of key performance metrics, focusing on brand gains and losses, industry contact rates, familiarity and adoption rates of recently launched products and awareness of products in development. This ongoing, independent insights series allows marketing professionals to keep abreast of and quickly react to market changes by providing critical information that will support their commercial strategies in the IBD space.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.